ACET Stock Forecast & Price Target

Adicet Bio is attractive because prula-cel has generated unusually strong clinical efficacy in heavily pretreated lupus nephritis and SLE patients, with 50% complete renal response at 12 months, 54% DORIS remission, and all responses remaining ongoing through 12 to 21 months. The dataset also shows meaningful biomarker evidence of immune reset, rapid and sustained disease-score improvements, and a safety profile with no CRS above Grade 2, no ICANS, no IEC-HS, and no GvHD, which supports outpatient dosing and differentiates it from paused autologous competitors. The FDA-aligned pivotal single-arm LN study, expected to initiate next quarter, is relatively small and efficient, while possible expansion into non-nephritis lupus could address an estimated 70,000 U.S. patients and materially broaden the commercial opportunity.

Adicet Bio is a clinical-stage biotech with a highly uncertain outlook because its lead programs face meaningful clinical, regulatory, and commercial risk, including the possibility that ADI-001 or related candidates may not prove efficacious or could encounter safety signals that halt development. The investment case is also weakened by modest assumed probabilities of approval—50% for ADI-001 in LN and 25% in LN/SLE—which underscore how dependent valuation is on a narrow set of outcomes rather than established product sales. In addition, slower-than-expected development, lower-than-projected commercial success, and possible medium- to long-term equity dilution risk increase the likelihood of value erosion.